The contribution of the complement system to the control of tumour growth has been
neglected for a long time as the major emphasis has been put mainly on cell-mediated
immune response against cancer. With the introduction of monoclonal antibodies in cancer
immunotherapy complement has come into play with a great potential as effector system.
Complement has a number of advantages over other effector systems in that it is made of
molecules that can easily penetrate the tumour tissue and a large majority, if not all, of the …